Alumis Inc. (ALMS)
| Market Cap | 1.34B +177.4% |
| Revenue (ttm) | 7.40M -63.1% |
| Net Income | -438.96M |
| EPS | -3.80 |
| Shares Out | 129.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,382,833 |
| Open | 10.16 |
| Previous Close | 9.47 |
| Day's Range | 9.95 - 10.77 |
| 52-Week Range | 3.76 - 31.35 |
| Beta | -0.79 |
| Analysts | Strong Buy |
| Price Target | 32.33 (+212.37%) |
| Earnings Date | Aug 13, 2026 |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ALMS stock is "Strong Buy." The 12-month stock price target is $32.33, which is an increase of 212.37% from the latest price.
News
Alumis price target lowered to $37 from $55 at Oppenheimer
Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $37 from $55 and keeps an Outperform rating on the shares. Alumis’s 58% intraday decline following the disappointing Phase 2b…
Alumis price target lowered to $25 from $51 at Wells Fargo
Wells Fargo lowered the firm’s price target on Alumis (ALMS) to $25 from $51 and keeps an Overweight rating on the shares. The firm says the stock move seems overdone,…
Alumis price target lowered to $29 from $39 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Alumis (ALMS) to $29 from $39 and keeps an Overweight rating on the shares. The firm is removing envudeucitinib’s SLE indication from…
Alumis upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Alumis (ALMS) to Buy from Neutral with a price target of $15, down from $25. The firm believes the LUMUS study miss removes systemic lupus erythematosus from…
Alumis price target lowered to $27 from $35 at Baird
Baird lowered the firm’s price target on Alumis (ALMS) to $27 from $35 and keeps an Outperform rating on the shares.
Alumis price target lowered to $25 from $51 at Wells Fargo
Wells Fargo lowered the firm’s price target on Alumis (ALMS) to $25 from $51 and keeps an Overweight rating on the shares after the company’s Phase 2b trial of envudeucitinib…
A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It
Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage trial.
Alumis eyes late-stage lupus study despite trial miss
Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a ...
Alumis Transcript: Study result
Envudeucitinib did not meet primary or secondary endpoints in the overall SLE population, but showed robust efficacy and a favorable safety profile in the IFNGS-high subgroup. Future development will focus on this biomarker-defined group, with regulatory engagement planned by year-end.
Alumis Press release: Study result
Alumis issued a press release on September 1, 2026, disclosing material business information to investors.
Alumis Slides: Study result
Alumis has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Alumis reports LUMUS trial did not meet primary, secondary endpoints
Alumis (ALMS) announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus did not meet its primary and secondary endpoints in the ove...
Alumis trading halted, news pending
07:28 EDT Alumis (ALMS) trading halted, news pending
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-...
Alumis reports Q2 revenue $1.66M, consensus $3.47M
“Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Ph...
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
Alumis Earnings release: Q2 2026
Alumis released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Alumis Quarterly report: Q2 2026
Alumis has published its Q2 2026 quarterly earnings report on August 13, 2026.
Alumis announces topline results from ONWARD3 long-term extension study
Alumis (ALMS) announced topline results from the ongoing ONWARD3 long-term extension study. Data confirm envudeucitinib delivered leading skin clearance and the highest reported Psoriasis Area and Sev...
Alumis Slides: Corporate presentation
Alumis has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Alumis management to meet with Cantor
Meeting to be held in London on June 30 and in Zurich on July 1 hosted by Cantor.